Pages that link to "Q40353912"

The following pages link to A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis (Q40353912):

Displaying 43 items.

• Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. (Q38597229) (← links)
• Giant Cell Arteritis - Beyond temporal artery biopsy and steroids. (Q39293033) (← links)
• Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities (Q40041736) (← links)
• Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2) (Q40201293) (← links)
• A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis (Q40353901) (← links)
• Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients (Q47104190) (← links)
• The European Vasculitis Society 2016 Meeting Report (Q47107377) (← links)
• Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia (Q47419344) (← links)
• Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. (Q47583915) (← links)
• Profile of tocilizumab and its potential in the treatment of giant cell arteritis. (Q49215677) (← links)
• Giant Cell Arteritis: Practical Pearls and Updates (Q49980652) (← links)
• Current and emerging therapies in large-vessel vasculitis (Q50082820) (← links)
• Vasculitis syndromes: Tocilizumab - a new frontier for GCA therapy (Q50212292) (← links)
• Checks and Balances in Autoimmune Vasculitis. (Q51764698) (← links)
• Investigational drugs in systemic vasculitis (Q51834131) (← links)
• Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. (Q52578815) (← links)
• Recent Advances in Giant Cell Arteritis. (Q52611166) (← links)
• Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. (Q52718727) (← links)
• Personalized Biologic Therapy for Large Vessel Vasculitis: Comment on the Articles by Langford et al. (Q53415506) (← links)
• FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. (Q54238129) (← links)
• Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. (Q54943677) (← links)
• Current treatment options for psoriatic arthritis: spotlight on abatacept. (Q55318901) (← links)
• Giant cell arteritis: early diagnosis is key (Q61446893) (← links)
• The Treatment of Giant Cell Arteritis in Different Clinical Settings (Q61810274) (← links)
• Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis (Q64247941) (← links)
• Current advances in the treatment of giant cell arteritis: the role of biologics (Q64250024) (← links)
• Clinical Reasoning: A 77-year-old man presenting with episodic expressive aphasia (Q88669623) (← links)
• Polymyalgia rheumatica (Q88678153) (← links)
• Arterial lesions in giant cell arteritis: A longitudinal study (Q89029803) (← links)
• Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors (Q89500035) (← links)
• [Treatment of giant cell arteritis and polymyalgia rheumatica] (Q89799884) (← links)
• Recent advances in the diagnosis and management of giant cell arteritis (Q90301638) (← links)
• A new era for giant cell arteritis (Q90468059) (← links)
• Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study (Q90678634) (← links)
• [Polymyalgia rheumatica and Giant Cell Arteritis - Update on Diagnosis and Therapy] (Q90793803) (← links)
• Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis (Q92332710) (← links)
• Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets (Q92464575) (← links)
• Leveraging Genetic Findings for Precision Medicine in Vasculitis (Q92712513) (← links)
• Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen (Q92737300) (← links)
• CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis (Q93036340) (← links)
• Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study (Q93158326) (← links)
• Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica (Q98222381) (← links)
• High-Sensitivity C-Reactive Protein and Magnetic Resonance Imaging in Occult Giant Cell Arteritis (Q98290779) (← links)